30 Sep 2011: It is referred to the Extraordinary General Meeting in NorDiag ASA held today, 30 September 2011.

NorDiag ASA makes it clear that the rights issue is not underwritten with an amount of NOK 15,000,000, and if the amount is not underwritten, the Board may cancel the rights issue, cf. section 6 j) of the Minutes of General Meeting.

For further information, please contact:

CEO Mårten Wigstøl       Phone: +47 911 65775
CFO Tone Kvåle              Phone: +47 915 19576
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com

Read the notice in Norwegian here